Fluorescent Label Patents (Class 436/546)
-
Patent number: 6815169Abstract: The invention provides isolated nucleic acid and amino acid sequences of TL-&ggr;, antibodies to TL-&ggr;, methods of screening for TL-&ggr; modulators using biologically active TL-&ggr;, and kits for screening for TL-&ggr; modulators.Type: GrantFiled: November 28, 2000Date of Patent: November 9, 2004Assignee: The Regents of the University of CaliforniaInventors: Roman Sakowicz, Lawrence S. B. Goldstein
-
Patent number: 6812036Abstract: A homogeneous assay for determining the deoxynivalenol (DON) content in grains uses the technique of fluorescence polarization. A grain extract is prepared by shaking a crushed grain sample with water. A mixture is prepared by combining the grain extract with a tracer and with monoclonal antibodies specific to DON. The tracer is able to bind to the monoclonal antibodies to produce a detectable change in fluorescence polarization. The tracer is prepared by conjugating DON to a suitable fluorophore. The fluorescence polarization of the mixture is measured. The DON concentration of the mixture may be calculated using a standard curve obtained by measuring the fluorescence polarization of a series of DON solutions of known concentration.Type: GrantFiled: July 11, 2001Date of Patent: November 2, 2004Assignee: Diachemix LLCInventors: Mohammad Sarwar Nasir, Michael E. Jolley
-
Patent number: 6808939Abstract: Bipyridine or phenanthroline ligands presenting functional groups that prevent non-specific binding (in particular, negatively charged functional groups that are unaffected by standard conditions for conjugating biological reagents through amide bonds) are described as are luminescent metal complexes comprising these ligands. The use of luminescent ruthenium and osmium complexes comprising these ligands in electrochemiluminescence assays shows that the use of these labels can significantly reduce the amount of non-specific binding observed relative to assays carried out using reagents labeled with analogous labels that don't present functional groups that decrease non-specific binding.Type: GrantFiled: June 29, 2001Date of Patent: October 26, 2004Assignees: IGEN International, Inc., BioVeris CorporationInventors: George B. Sigal, Howie Tjiong, Liwen Dong, Md. Athar Masood, Richard C. Titmas
-
Publication number: 20040197844Abstract: Use of pregnancy-associated plasma protein-A as a marker for inflammatory conditions, and in particular, for acute coronary syndromes is described.Type: ApplicationFiled: January 29, 2004Publication date: October 7, 2004Applicant: Mayo Foundation for Medical Education and Research, a Minnesota CorporationInventors: Cheryl A. Conover, Antonio Bayes-Genis, David R. Holmes, Robert S. Schwartz
-
Patent number: 6794496Abstract: The present invention provides hapten derivatives useful for the preparation of antigens, antibodies and reagents for use in immunoassays for the detection of LSD and 2-oxo-3-hydroxy LSD. In the present invention, the 2-oxy LSD nucleus is derivatized out of the indole nitrogen to form an aminoalkyl derivative. The resulting haptens can then be further modified at this functionalized position for linking to appropriate immunogenic or labeling groups to provide reagents for immunoassays having substantially equal specificity for both LSD and 2-oxo-3-hydroxy-LSD.Type: GrantFiled: December 8, 2000Date of Patent: September 21, 2004Assignee: Roche Diagnostics CorporationInventors: Mitali Ghoshal, Stephen Vitone, Gerald F. Sigler, Alan J. McNally
-
Patent number: 6787325Abstract: Provided are novel complexes containing a crosslinked avidin, an analyzing method and analyzing reagents and kits whereby a compound to be analyzed can be quickly, conveniently and accurately analyzed while taking advantage of the avidin-biotin reaction. The complexes contain at least two homogeneous or heterogeneous biotin-introduced products and one crosslinked avidin sandwiched therebetween. In the analyzing method, the homogeneous or heterogeneous biotin-introduced products and the crosslinked avidin are used. The analyzing reagent contains the crosslinked avidin. The analyzing kit contains the crosslinked avidin and a biotinylating agent.Type: GrantFiled: July 5, 2000Date of Patent: September 7, 2004Assignees: Iatron Laboratories, Inc., Kikkoman CorporationInventors: Kazuyuki Sugiyama, Nobuhiro Hoshino, Hiroki Tatsumi, Satoshi Fukuda
-
Patent number: 6780581Abstract: A method for the production of a product containing a quantum of bioparticles, for example bacterial cells, is provided, as are products obtained thereby. In one embodiment, the products contain a defined quantum of bioparticles, preferably presented in a viable state. Products made in accordance with the invention may be usefully put to applications where having knowledge of the number of bioparticles present may be important or at least advantageous.Type: GrantFiled: September 12, 2001Date of Patent: August 24, 2004Assignee: BTF Pty LtdInventors: Graham Vesey, Mark Gauci
-
Patent number: 6777246Abstract: A reagent for use in immunoassays reduces interference in particle agglutination assays. The reagent contains particles having covalently bound antibodies and a tertiary amine compound of formula (I): N(R1—X)(R2—Y)(R3—Z) (I). The moieties R1, R2, and R3 are independently alkyl or alkyl ether. The moieties X, Y, and Z are independently —OH, —O—R4, —S—R4, —C(═O)—OH, —C(═O)—OR4, or —C(═O)—NHR4 (R4 is alkyl).Type: GrantFiled: December 18, 2001Date of Patent: August 17, 2004Assignee: Roche Diagnostics GmbHInventors: Christopher C. Lawrence, Armen B. Shanafelt
-
Patent number: 6773928Abstract: Compositions of matter and methods for enhancing bioassay performance are disclosed. More particularly, the composition of matter comprises a molecularly compact polymer-ligand conjugate capable of self-orienting on a surface to improve the orientation of the ligand/receptor binding domains within the bioassay at the nanoscopic level. In a preferred embodiment, the molecularly compact polymer comprises a dendrimer polymer such as a fifth generation polyamidoamine dendrimer having exterior surface hydroxyl and amine functional groups, and the ligand/receptor comprises an antibody or Fab.Type: GrantFiled: August 27, 2001Date of Patent: August 10, 2004Assignee: The United States of America as represented by the Secretary of the ArmyInventors: Ray Yin, H. Dupont Durst, Peter A. Emanuel, Gary L. Hagnauer
-
Patent number: 6774361Abstract: A novel encoding system and methods for determining the location and/or identity of a particular item or component of interest is provided. In particular, the present invention utilizes a “barcode” comprising one or more sizes of semiconductor nanocrystals (quantum dots) having characteristic spectral emissions, to either “track” the location of a particular item of interest or to identify a particular item of interest. The semiconductor nanocrystals used in the inventive “barcoding” scheme can be tuned to a desired wavelength to produce a characteristic spectral emission in narrow spectral widths, and with a symmetric, nearly Gaussian line shape, by changing the composition and size of the quantum dot. Additionally, the intensity of the emission at a particular characteristic wavelength can also be varied, thus enabling the use of binary or higher order encoding schemes.Type: GrantFiled: May 30, 2002Date of Patent: August 10, 2004Assignee: Massachusetts Institute of TechnologyInventors: Moungi G. Bawendi, Klavs F. Jensen
-
Patent number: 6759206Abstract: The present invention provides systems, methods, and screens to measure receptor internalization in a single step with appropriate automation and throughput. This approach involves luminescent labeling of the receptor of interest and the automated measurement of receptor internalization to a perinuclear location.Type: GrantFiled: July 12, 1999Date of Patent: July 6, 2004Assignee: Cellomics, Inc.Inventors: Richard A. Rubin, Kenneth A. Giuliano, Albert H. Gough, R. Terry Dunlay
-
Patent number: 6756207Abstract: The present invention provides systems, methods, screens, reagents and kits for optical system analysis of cells to rapidly determine the distribution, environment, or activity of fluorescently labeled reporter molecules in cells for the purpose of screening large numbers of compounds for those that specifically affect particular biological functions.Type: GrantFiled: October 29, 1999Date of Patent: June 29, 2004Assignee: Cellomics, Inc.Inventors: Kenneth A. Giuliano, Gary Bright, Keith Olson, Sarah Burroughs Tencza
-
Patent number: 6753156Abstract: The invention relates to a novel homogeneous method of detecting and/or determining the phosphorylating activity of a biological material towards a substrate containing tyrosine and/or serine and/or threonine, and to a kit for carrying out this method.Type: GrantFiled: March 6, 2000Date of Patent: June 22, 2004Assignee: Cis Bio InternationalInventors: Gérard Mathis, Eric Trinquet, Marc Preaudat
-
Patent number: 6753153Abstract: The differential expression of marker proteins in a targeted population provides a means of identifying and isolating cells. A population of cells associated with the regeneration of pancreatic islets is shown to express certain proteins, including the cell surface proteins ErbB2, ErbB3, and ErbB4; and the nuclear protein Msx-2. Populations of isolated pancreatic islet progenitor cells find use in screening assays, to characterize genes involved in islet development and regulation, and in transplantation to provide a recipient with pancreatic islet functions.Type: GrantFiled: December 13, 2000Date of Patent: June 22, 2004Assignee: The Scripps Research InstituteInventors: Nora Sarvetnick, Marcie Kritzik
-
Patent number: 6750034Abstract: Here we describe the molecular identification of a cDNA encoding a novel serine protease we have termed D-G. The deduced amino acid sequence, and it's alignment with other well characterized serine proteases clearly indicates that it is a member of the S1 serine protease family. We have found that the protease D-G mRNA is widely expressed in several tissues throughout the body including epidermis, fibroblasts, keratinocytes, colon, small intestine, stomach, lung, kidney, bone marrow, lymph node, thymus, ovary, prostate, uterus and spinal cord. Interestingly, this protease contains a hydrophobic stretch of amino acids which is a putative transmembrane near the NH2-terminus. Thus, this serine protease is thought to be synthesized as a type II integral protein.Type: GrantFiled: June 30, 2000Date of Patent: June 15, 2004Assignee: Ortho-McNeil Pharmaceutical, Inc.Inventors: Andrew L. Darrow, Jenson (Jian-Shen) Qi, Patricia Andrade-Gordon
-
Patent number: 6747135Abstract: The present invention is directed to novel polypeptides, termed fluorettes, that bind with high avidity to fluorophore dyes. The peptides find use in a variety of methods and approaches involving fluorophore dyes.Type: GrantFiled: October 15, 1999Date of Patent: June 8, 2004Assignee: The Board of Trustees for the Leland Stanford Junior UniversityInventors: Garry P. Nolan, Michael N. Rozinov
-
Patent number: 6743591Abstract: A method for counting leukocytes which comprises liberating elastase from granulocytes contained in a specimen, adding an anti-granulocyte elastase antibody to the thus liberated elastase, measuring the antibody bonded to the elastase to thereby determine the concentration of the elastase, and then calculating therefrom the number of leukocytes contained in the specimen with the use of the ratio of the leukocyte count to the elastase concentration. This method makes it possible to conveniently and less expensively count leukocytes at a high accuracy comparable to the one established by using a conventional automatic blood cell counter, as the figure shows.Type: GrantFiled: August 31, 2000Date of Patent: June 1, 2004Assignee: Arkray, Inc.Inventors: Akio Okubo, Shigeki Yamada
-
Patent number: 6740257Abstract: Disclosed is a modular fluorescence sensor having the following general formula: Where Fl is a fluorophore, N is a nitrogen atom, Bd1 and Bd2 are independently selected binding groups, Sp is an aliphatic spacer, and An is an anchor group for attaching the sensor to solid substrates. n=1 or 2, m=1 or 2, x is an integer, and y=1 or 2. The binding groups are capable of binding an analyte molecule to form a stable 1:1 complex. In a preferred embodiment, the Bd1 is R1—B(OH)2 and Bd2 is R2—B(OH)2. R1 and R2 are aliphatic or aromatic functional groups selected independently from each other and B is a boron atom. The present invention also provides methods of synthesizing a modular fluorescence sensor and its use in labeling solid substrates.Type: GrantFiled: January 17, 2002Date of Patent: May 25, 2004Assignee: Beckman Coulter, Inc.Inventors: Susumu Arimori, Tony D. James
-
Patent number: 6740495Abstract: The invention relates to assays for measuring ubiquitin ligase activity and for identifying modulators of ubiquitin ligase enzymes.Type: GrantFiled: April 3, 2000Date of Patent: May 25, 2004Assignee: Rigel Pharmaceuticals, Inc.Inventors: Sarkiz D. Issakani, Jianing Huang, Julie Sheung
-
Patent number: 6737279Abstract: The present invention provides a method of detecting a biological agent including contacting a sample with a sensor including a polymer system capable of having an alterable measurable property from the group of luminescence, anisotropy, redox potential and uv/vis absorption, the polymer system including an ionic conjugated polymer and an electronically inert polyelectrolyte having a biological agent recognition element bound thereto, the electronically inert polyelectrolyte adapted for undergoing a conformational structural change upon exposure to a biological agent having affinity for binding to the recognition element bound to the electronically inert polyelectrolyte, and, detecting the detectable change in the alterable measurable property. A chemical moiety being the reaction product of (i) a polyelectrolyte monomer and (ii) a biological agent recognition element-substituted polyelectrolyte monomer is also provided.Type: GrantFiled: March 28, 2001Date of Patent: May 18, 2004Assignee: The Regents of the University of CaliforniaInventor: Liaohai Chen
-
Patent number: 6737280Abstract: A class of asymmetric monobenzoxanthene compounds useful as fluorescent dyes are disclosed having structure (I) wherein Y1 and Y2 are individually hydroxyl, amino, imminium, or oxygen, R1-R8 are hydrogen, fluorine, chlorine, alkyl, alkene, alkyne, sulfonate, amino, amido, nitrile, alkoxy, linking group, and combinatios thereof, and R9 is acetylene, alkane, alkene, cyano, substituted phenyl, and combinations thereof. The invention further includes novel intermediate compounds useful for the synthesis of asymmetric benzoxanthene compounds having general structure (II) where substituents R3-R7 correspond to like-referenced substituents in the structure of described above, and Y2 is hydroxyl or amine. In another aspect, the invention includes methods for synthesizing the above dye compounds and intermediates. In yet another aspect, the present invention includes reagents labeled with the asymmetric benzoxanthene dye compounds, including deoxynucleotides, dideoxynucleotides, phosphoramidites, and polynucleotides.Type: GrantFiled: November 26, 2001Date of Patent: May 18, 2004Assignee: Karl-Heinz DrexhageInventors: Karl-Heinz Drexhage, Jutta Arden-Jacob, Norbert Kemnitzer
-
Patent number: 6737244Abstract: The invention relates to assays for measuring ubiquitin ligase activity and for identifying modulators of ubiquitin ligase enzymes.Type: GrantFiled: April 3, 2001Date of Patent: May 18, 2004Assignee: Rigel Pharmaceuticals, Inc.Inventors: Sarkiz D. Issakani, Jianing Huang, Julie Sheung, Todd R. Pray
-
Patent number: 6727071Abstract: The present invention provides systems, methods, and screens for an optical system analysis of cells to rapidly determine the distribution, environment, or activity of fluorescently labeled reporter molecules in cells for the purpose of screening large numbers of compounds for those that specifically affect particular biological functions. The invention involves providing cells containing fluorescent reporter molecules in an array of locations and scanning numerous cells in each location with a high magnification fluorescence optical system, converting the optical information into digital data, and utilizing the digital data to determine the distribution, environment or activity of the fluorescently labeled reporter molecules in the cells. The array of locations may be an industry standard 96 well or 384 well microtiter plate or a microplate which is microplate having cells in a micropaterned array of locations.Type: GrantFiled: December 8, 1999Date of Patent: April 27, 2004Assignee: Cellomics, Inc.Inventors: R. Terry Dunlay, D. Lansing Taylor, Albert H. Gough, Kenneth A. Giuliano
-
Patent number: 6723567Abstract: The present invention relates to a method for the determination of non-, anti-, or pro-apoptotic and necrotic conditions of cells, newly designed vectors coding for marker proteins, cell lines transfected with such vector, and a method to assay the non-, pro- or anti-apoptotic or necrotic activity of test compounds.Type: GrantFiled: September 19, 2000Date of Patent: April 20, 2004Assignee: Aponetics Ltd.Inventors: Thomas Harr, Alessandro Strebel, Peter Erb, Sinuhe Hahn
-
Patent number: 6720192Abstract: A method for assaying an analyte in a sample. The method comprising the steps of a) contacting the sample with material comprising a receptor which is present in a liposome and which liposome comprises a detectable functionality, said contact occurring under conditions resulting in binding of the receptor to analyte if present before or concomitant with step b, wherein step b) consists of contacting the sample with an immobilised ligand for the receptor said contact occurring under conditions resulting in binding of the receptor to the ligand, with steps a and b being followed by c) separating the resulting immobilised ligand-receptor fraction and the receptor fraction present in solution and d) assaying the detectable functionality of the receptor in a fraction from step c) in a manner known per se for its detection.Type: GrantFiled: May 9, 2001Date of Patent: April 13, 2004Assignee: Merska B.V.Inventors: Gerhard Theodoor Viel, Kornelis Ensing
-
Patent number: 6716640Abstract: The invention concerns the stabilization and amplification of electrochemiluminescence signals in detection methods.Type: GrantFiled: May 11, 2001Date of Patent: April 6, 2004Assignee: Roche Diagnostics GmbHInventors: Gabriele Punzmann, Martin Egger, Hans-Peter Josel
-
Patent number: 6706490Abstract: A predictive test for rheumatoid arthritis comprises the detection of antibodies to collagen in a biological sample from a patient by contacting the biological sample with an antigen comprising the CB10 peptide of mammalian type II collagen, or an antibody-binding fragment or variant thereof, for a time and under conditions for an antibody-antigen complex to form, and detecting the antibody-antigen complex, for example by immunoassay. A diagnostic test kit is also disclosed.Type: GrantFiled: November 20, 2000Date of Patent: March 16, 2004Assignees: Montech Medical Developments Pty. Ltd., Rondole Pty. Ltd.Inventors: Andrew Cook, Merrill Rowley, Ian Mackay
-
Patent number: 6703248Abstract: Methods, compositions and kits are disclosed. The compositions are light emitting and comprise a polymeric matrix having dissolved therein a photoactive compound. The composition has the characteristic that, after activation of the photoactive compound, the rate of decrease in the intensity of light emission at any time during a 20-fold decrease in the intensity is proportional to the intensity of the light emission. In one embodiment the polymeric matrix is comprised of particles of about 20 nm to about 100 &mgr;m in diameter to which is bound a specific binding pair member. The particles generally comprise a polymeric matrix having dissolved therein about 1 to about 20% by weight of a dopant. The compositions may be used in methods for determining an analyte. A combination is provided comprising (1) a medium suspected of containing the analyte, (2) and the aforementioned composition.Type: GrantFiled: December 15, 1999Date of Patent: March 9, 2004Assignee: Dade Behring Marburg GmbHInventors: Sharat Singh, John S. Pease, Jacqueline Sadakian, Daniel B. Wagner, Edwin F. Ullman
-
Patent number: 6696304Abstract: A process, a test kit, calibration standards, and the method of preparing such standards as useful for the qualitative and/or quantitative determination of total solid phase- or microparticle-immobilized, amine-containing reactants such as proteins is provided. The operating principle of the invention is distinct from a classical immunoassay based on antibody-antigen immune interaction or from standard calorimetric proteins assays of soluble proteins and allows the detection of as low as attogram (10−18 gm) levels of total analyte per microparticle.Type: GrantFiled: February 24, 2000Date of Patent: February 24, 2004Assignee: Luminex CorporationInventor: Travis Parker Davies
-
Patent number: 6692975Abstract: Compositions are disclosed comprising (a) a metal chelate wherein the metal is selected from the group consisting of europium, terbium, dysprosium, samarium osmium and ruthenium in at least a hexacoordinated state and (b) a compound having a double bond substituted with two aryl groups, an oxygen atom and an atom selected from the group consisting of oxygen, sulfur and nitrogen wherein one of the aryl groups is electron donating with respect to the other. Such composition is preferably incorporated in a latex particulate material. Methods and kits are also disclosed for determining an analyte in a medium suspected of containing the analyte. The methods and kits employ as one component a composition as described above.Type: GrantFiled: November 2, 2001Date of Patent: February 17, 2004Assignee: Dade Behring Marburg GmbHInventors: Sharat Singh, Edwin F. Ullman
-
Patent number: 6689568Abstract: A method of evaluating for the presence of a polypeptide in an analyte, using an addressable array of capture agents linked to a substrate. The analyte is exposed to the array and a set of fixed capture agents, such that the target molecules will bind to the array by means of the capture agents. After the target molecule has bound to the capture agents, it is modified using a label. The label does not interact or mark the capture agent. Kits using such arrays are further provided.Type: GrantFiled: February 1, 2001Date of Patent: February 10, 2004Assignee: Agilent Technologies, Inc.Inventor: Joel Myerson
-
Patent number: 6686209Abstract: In this disclosure, novel caanabinol-based tracers suitable for use in immunoassays that detect cannabinoids in a biological sample are disclosed. These cannabinol-based tracers are particularly useful in a continuous flow displacement immunoassay. The disclosure also describes the processes for synthesizing the novel tracers, and the application of these tracers in fluorescence immunoassays for detecting and quantifying cannabinoids in biological samples.Type: GrantFiled: March 12, 2001Date of Patent: February 3, 2004Assignee: Lifepoint, Inc.Inventors: Guohong Wang, Thomas Foley, Connie Chang, Greg Liang, Albert Avila
-
Patent number: 6677164Abstract: The present invention provides biologically active linear polypeptides that possess a plurality of biologically active groups, methods employing such peptides to target molecules to cells, and methods employing such peptides for inhibiting the binding of cells to each other.Type: GrantFiled: June 11, 1998Date of Patent: January 13, 2004Assignee: Novartis AGInventors: Gebhard Thoma, Rudolf Duthaler, Beat Ernst, John Louis Magnani, John Tinsman Patton, Jr.
-
Patent number: 6670193Abstract: The present invention provides fluorescent nucleoside analogs which comprise a fluorescent cyclic compound joined to a carbon of a sugar molecule such as pentose, hexose, ribose or deoxyribose or analogs thereof in either an &agr; or &bgr; configuration. The subject compounds are useful as probes in the study of the structure and dynamics of nucleic acids and their complexes with proteins. In addition, the subject compounds are useful in any technique which uses labeled oligonucleotides for detection. Non-fluorescent spacer molecules in which a cyclohexane, cyclohexene, decalin, or benzene is joined to a carbon of a sugar moiety such as pentose, hexose, ribose or deoxyribose are also provided. Also provided are the 5′ dimethoxytrityl-3′-O-phosphoramidite derivatives, suitable for incorporation into oligonucleotides by automated synthesizers.Type: GrantFiled: April 19, 2002Date of Patent: December 30, 2003Assignee: Research Corporation Technologies, Inc.Inventor: Eric T. Kool
-
Patent number: 6667179Abstract: The invention provides methods and compositions for detecting binding or unbinding of a molecule to a substrate. The molecule comprises a luminophore and the substrate comprises a semiconductor which acts as a luminescence quencher to provide distance-dependent quenching of the luminophore. Binding or unbinding of the molecule, which may be covalent or noncovalent, is detected as a decrease or increase, respectively, of the detectable luminescence of the luminophore.Type: GrantFiled: October 28, 1999Date of Patent: December 23, 2003Assignee: The Board of Trustees of the University of IllinoisInventor: Paul R. Selvin
-
Patent number: 6664071Abstract: A device for the detection of electromagnetic radiation, wherein the device has (i) a photoactive layer of a semiconductor having a band gap of greater than 2.5 eV, (ii) a dye applied to the semiconductor, and (iii) a charge transport layer comprising a hole conductor material, where the hole conductor material is preferably solid and amorphous.Type: GrantFiled: September 26, 2000Date of Patent: December 16, 2003Assignee: Nanogen Recognomics GmbHInventors: Norbert Windhab, Hans-Ulrich Hoppe, Donald Lupo
-
Patent number: 6660486Abstract: Analyses of serum samples for the presence and amount of either of the two subunits of human Factor XIII protein are used as a means of eliminating a significant source of error that arises in the testing of serum and plasma. For serum samples, a negative result of an analysis for the presence of subunit a is a means of verifying that a sample is indeed serum, while a negative or positive result for subunit a serves to distinguish serum (negative) from plasma (positive). A positive result for the presence of subunit b is a means of verifying that the sample is either serum or plasma and not any other biological fluid. A quantitative analysis of subunit b is a means of verifying that the sample is of the intended volume rather than having been reduced in volume due to improper sampling. A quantitative analysis of subunit b is also a means of verifying the dilution of a sample of either serum or plasma.Type: GrantFiled: May 31, 2001Date of Patent: December 9, 2003Assignee: Bio-Rad Laboratories, Inc.Inventors: Steven R. Binder, Jodi L. Goodrich, Zara Safarian
-
Patent number: 6656696Abstract: This invention relates to methods and compositions for monitoring the interaction of binding partners as a function of the addition or subtraction of a phosphate group to or from one of the binding partners by a protein kinase or phosphatase.Type: GrantFiled: February 26, 1999Date of Patent: December 2, 2003Assignee: CyclacelInventors: Roger K. Craig, John Colyer
-
Patent number: 6653066Abstract: Disclosed is a device and method of use for detecting polyvalent analytes such as antibody to the AIDS virus, utilizing an inverse sandwich method. The test device comprises a first substance having an epitope, bound to a label and capable of moving within the test device. The test device further comprises a second substance immobilized to the test device and spatially separated from the first substance. The second substance has an epitope substantially similar to the epitope of the first substance. Upon application to the test device, the polyvalent analyte binds to the first substance and moves within the test device to the location of the second substance with both polyvalent analyte and first substance are immobilized at location of the second substance. Polyvalent analyte is detected by the presence of the label at the location of the second substance. Also disclosed is a control substance for use with the device that can be used to determine completion of the test and viability of the device.Type: GrantFiled: June 17, 1994Date of Patent: November 25, 2003Assignee: Trinity BiotechInventor: Siegfried R. Krutzik
-
Patent number: 6649418Abstract: The present invention provides internally calibrated competitive assays for use on a solid support. Additionally, the invention provides a method of using such assays.Type: GrantFiled: July 30, 2001Date of Patent: November 18, 2003Assignee: Silver Lake Research CorporationInventor: Mark S. Geisberg
-
Patent number: 6645724Abstract: The horseshoe crab, Carcinoscorpius rotundicauda Factor C cDNA (CrFC21) has been cloned into a shuttle baculoviral vector and another vector suitable for expression in insect cells. The recombinant baculoviral DNA was then transfected into the insect cells for expression of recombinant Factor C. Recombinant Factor C was found to be immunoreactive and is capable of binding both free and bound/immobilized lipid A. It is enzymatically active when triggered by LPS. The rFC is probably of the two-chain form, being cleaved into the heavy and light chains after activation by Gram negative bacterial endotoxin. As low as 0.01 pg (0.001 ng/ml) of LPS was detectable by the rFC, thus, indicating its potentials as a novel generation of “limulus amoebocyte lysate.Type: GrantFiled: April 7, 1999Date of Patent: November 11, 2003Assignee: National University of SingaporeInventors: Jeak Ling Ding, Bow Ho
-
Patent number: 6635434Abstract: A hapten-polymer carrier complex was found to be useful for immunoassay purposes, specifically ELISAs, for the detection of pesticides and their degradation products in hydrosoil and ground water. The degradation products of Casoron G® (also known as dichlorobenzonitrile and dichlorbenil) and Prefix® (also known as chlorthiamid and dichlorobenzthiamide) are analytes detected with high specificity and sensitivity, particularly the degradation product BAM (2,6-dichlorobenzamide). The polymer carrier complex is bound to the hapten via a linker unit, strategically positioned meta to the amide or amide derivative of BAM.Type: GrantFiled: July 21, 2000Date of Patent: October 21, 2003Assignee: Exiqon A/SInventors: Mogens Havsteen Jakobsen, Leif Bruun, Brian Pedersen
-
Patent number: 6632624Abstract: The invention pertains to an immunoassay, and a kit for said assay, in which at least one monoclonal antibody or polyclonal antibody specifically binds to an epitope corresponding to amino acids 145 to 234 of human chromogranin A.Type: GrantFiled: November 14, 2000Date of Patent: October 14, 2003Assignee: CIS bio InternationalInventors: François Degorce, Laurent Bellanger, Dominique Aunis
-
Patent number: 6630311Abstract: The invention relates to novel fluorescence-based assays for protein kinases and phosphatases which can be used in high throughput screening. The methods of the invention utilize a competitive immunoassay to determine the amount of substrate that is phosphorylated or dephosphorylated during the course of a kinase or phosphatase reaction to yield a product, as well as the phosphorylating or dephosphorylating activity of a kinase or phosphatase.Type: GrantFiled: December 6, 2000Date of Patent: October 7, 2003Assignee: Pharmacia & Upjohn CompanyInventors: Dennis E. Epps, Charles K. Marschke
-
Patent number: 6630355Abstract: A magnetic focusing immunosensor for the detection of pathogens comprising a laser, an exciting fiber and a collecting fiber, a fiber optic magnetic probe in communication with the collecting and exciting fibers and means for detecting, collecting and measuring fluorescent signals in communication with the collecting fiber. The probe and the collecting and exciting fibers are configured to focus paramagnetic microspheres attached to antigen/antibody/optically labeled complexes in a predetermined pattern in the field of view of the collecting fiber while blocking background interference.Type: GrantFiled: January 2, 2001Date of Patent: October 7, 2003Assignees: The Board of Governors for Higher Education State of Rhode Island, Providence PlantationInventors: Philip Pivarnik, He Cao, Stephen V. Letcher, A. Garth Rand
-
Patent number: 6630307Abstract: The use of semiconductor nanocrystals as detectable labels in various chemical and biological applications is disclosed. The methods find use for detecting a single analyte, as well as multiple analytes by using more than one semiconductor nanocrystal as a detectable label, each of which emits at a distinct wavelength.Type: GrantFiled: June 21, 2001Date of Patent: October 7, 2003Assignee: Quantum Dot CorporationInventors: Marcel P. Bruchez, R. Hugh Daniels, Stephen A. Empedocles, Vince E. Phillips, Edith Y. Wong, Donald A. Zehnder
-
Patent number: 6630570Abstract: The invention relates to compounds for tumor diagnosis that consist of conjugates of dyes with short-chain peptides, which are derived from vaso-active intestinal peptide, somatostatin or neurotensin, the use of these compounds as optical dignostic agents, and diagnostic agents that contain these compounds.Type: GrantFiled: March 17, 2000Date of Patent: October 7, 2003Assignee: Insitut für Diagnostikforschung GmbHInventors: Kai Licha, Andreas Becker, Wolfhard Semmler, Bertram Wiedenmann, Carsten Hessenius, Rudolf Volkmer-Engert, Jens Schneider-Mergner
-
Patent number: 6623981Abstract: This invention relates to the detection of patients at risk for developing integrin antagonist/agonist mediated disease states. This invention relates to assays useful for the detection in a patient bodily fluid sample of drug-dependent antibodies which bind to integrins, or intergrin-associated proteins or complexes thereof in the presence of an integrin antagonist/agonist. This invention also relates to assays useful for the detection in a patient bodily fluid sample of drug-dependent antibodies (DDABS) that bind to integrins, including the platelet glycoprotein IIb/IIIa (GPIIb/IIIa), in the presence of a integrin agonist and/or antagonist. This invention also relates to procedures for identifying integrin antagonists/agonists that are less prone to elicit integrin antagonist/agonist mediated disease states. This invention also relates to procedures which increase the recovery of integrin-directed antibodies in body fluids, resulting in an increased sensitivity and specificity of DDAB detection assays.Type: GrantFiled: January 26, 1999Date of Patent: September 23, 2003Assignee: Bristol-Myers Squibb CompanyInventors: Jeffrey T. Billheimer, Dietmar A. Seiffert, Leah A. Breth, Timothy C. Burn, Ira B. Dicker, Henry J. George, Gregory F. Hollis, Jeannine M. Hollis, Jennifer E. Kochie, Karyn T. O'Neil
-
Patent number: 6620591Abstract: The invention relates to an optical system for determining the distribution, environment, or activity of fluorescently labeled reporter molecules in cells for the purpose of screening large numbers of compounds for specific biological activity. The invention involves providing cells containing fluorescent reporter molecules in an array of locations and scanning numerous cells in each location with a fluorescent microscope, converting the optical information into digital data, and utilizing the digital data to determine the distribution, environment or activity of the fluorescently labeled reporter molecules in the cells. The array of locations may be an industry standard 96 well or 384 well microtiter plate or a microplate which is a microplate having a cells in a micropaterned array of locations. The invention includes apparatus and computerized method for processing, displaying and storing the data.Type: GrantFiled: April 16, 1999Date of Patent: September 16, 2003Assignee: Cellomics, Inc.Inventors: R. Terry Dunlay, D. Lansing Taylor
-
Patent number: 6613535Abstract: This invention relates to a method for establishing and using a decision marker by which positive samples can be discriminated from negative samples. The method employs the analysis of multiple samples from confirmed positive and negative samples. A fluorescence channel is selected so that the desired sensitivity and specificity are achieved. A microparticle having this fluorescence channel then is made and is used in conjunction with a fluorescence marker which is specific for the population of interest.Type: GrantFiled: October 29, 1992Date of Patent: September 2, 2003Assignee: Becton, Dickinson andCompanyInventors: Joachim Albrecht, Frank Hulstaert, Rosette Becker